5 FTSE 100 growth stocks to buy in June

As investors flock to value stocks, G A Chester sees an opportunity to invest in these FTSE 100 growth stocks that have underperformed the market.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

FTSE 100 growth stocks are on my radar to buy right now. A number of such stocks have underperformed the index’s 9% rise so far this year. I think this could be a chance for me to invest in some quality businesses while they’re out of favour.

Here are five blue-chip companies that appeal to me today.

My FTSE 100 growth stocks to buy

Let’s begin by looking at the underperformance of their shares. The table below shows the performances of the FTSE 100 and the five stocks for the year to date and the last 12 months.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

 

Year to date (%)

Last 12 months (%)

FTSE 100

+9.0

+10.3

Avast

-13.8

-7.4

Experian

-3.5

-7.1

Hikma

-4.5

-0.6

Intertek

-5.5

-3.8

Reckitt

-3.2

-10.6

As you can see, my FTSE 100 growth stocks to buy have significantly underperformed the index over both periods. This is because investors have flocked to value and recovery plays.

Of course, growth stocks may remain out of favour for a while yet. But I expect the quality of my five picks to shine through in due course. As such, they’re businesses I’d like to buy a slice of for the long term.

Two technology-based companies

Avast is a major player in consumer cybersecurity and privacy. It doesn’t have a long history as a public company (little more than three years) which I see as something of a risk. However, I’ve been impressed by its performance and I like its significant market opportunity. A rating of 18 times forecast earnings looks good value to me for the potential long-term growth on offer.

Experian is the world’s leading credit reference agency. It has valuable data and analytical technology at its heart. There’s a risk the company could suffer reputational damage if its data is breached or misused. But I’m content to accept the risk to own a slice of this high-quality market leader. I’m also content to pay a relatively high 32 times forecast earnings.

The other FTSE 100 growth stocks I’d buy

I reckon healthcare is an attractive sector for me to invest in. Ageing populations and rising health spending in developing economies provide a backdrop for growth. I like Hikma Pharmaceuticals for its significant exposure to generic medicines and emerging markets. There can be difficulties in gaining regulatory approval for generics, but Hikma has a good record. I see value in its rating of 18 times forecast earnings.

Intertek is an industry leader in Total Quality Assurance. That’s to say, it helps ensure the quality and safety of companies’ products, processes and systems. Rising demand for quality assurance worldwide has helped put Intertek on my list of FTSE 100 growth stocks to buy. There’s some risk in the company’s acquisition strategy, but I’m prepared to accept both this and a rating of 28 times forecast earnings.

Finally, I’m a big fan of hygiene and health brands powerhouse Reckitt. Its true that the digital world has lowered the barriers for new brands to enter the market. However, I think Reckitt’s brands, like Dettol and Gaviscon, can continue to be popular and trusted. The company is investing for growth and I’m happy to pay 21 times forecast earnings.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Avast Plc, Experian, Hikma Pharmaceuticals, and Intertek. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

As the shares fall despite strong earnings, is this a cue to buy this top growth stock?

Airbnb stock is down despite accelerating sales growth. Stephen Wright thinks this could be his opportunity to buy its shares…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

2 cheap shares investors might consider buying right now, and one I wouldn’t touch

Harvey Jones examines three cheap shares from the FTSE 100 to see whether they really are the bargains they appear…

Read more »

Passive income text with pin graph chart on business table
Dividend Shares

Why passive income investors should consider these 3 defensive stocks in 2025

Ken Hall looks at three Footsie dividend stocks that could offer investors passive income even in tougher economic times.

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

3 high-flying UK stocks I’d love to buy in the next stock market dip

Harvey Jones is keen to go shopping for UK stocks but some of those on his list are a little…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£16,067 in savings? Here’s a smart passive income plan for investors to consider

Savers have many ways to make their money work hard for them. Here’s one to consider that might lead to…

Read more »

Two elderly people relaxing in the summer sunshine Box Hill near Dorking Surrey England
Investing Articles

2 shares I’m keen to buy if they become cheap enough

Christopher Ruane explains why he wants to buy this pair of shares when he spots the right moment -- but…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

1 top S&P 500 growth stock to consider buying before it soars

Robotaxi risks notwithstanding, our author thinks Uber might be one of the most impressive S&P 500 growth stocks around at…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

Could this penny stock be a millionaire-maker?

This penny stock has massively underperformed since its IPO. Dr James Fox explores whether there could be some value in…

Read more »